Heterozygous disruption of CMA1 does not affect blood pressure

Journal of Hypertension

Volumn 22, Issue 1, 2004, Pages 103-109

  Ono, Koh ^a   Kokubo, Yoshihiro ^a   Mannami, Toshifumi ^a   Inamoto, Nozomu ^a   Shioji, Keisuke ^a   Iwai, Naoharu ^a  

^a NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

Author keywords

Chymase; Epidemiology; Genetics; Hypertension

Indexed keywords

ANGIOTENSIN; ANTIHYPERTENSIVE AGENT;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; EXON; FEMALE; FRAMESHIFT MUTATION; GENE; GENE DISRUPTION; GENE FUNCTION; GENE MUTATION; GENE SEQUENCE; GENOTYPE; HETEROZYGOSITY; HETEROZYGOSITY LOSS; HUMAN; HYPERTENSION; INTRON; MAJOR CLINICAL STUDY; MALE; MAST CELL CHYMASE 1 GENE; PATHOGENESIS; POPULATION RESEARCH; PRIORITY JOURNAL; PROMOTER REGION; RNA SPLICING; SINGLE NUCLEOTIDE POLYMORPHISM; STOP CODON;

EID: 1442323642     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-200401000-00019     Document Type: Article

References (20)

1. Intengan HD, Thibault G, Li JS, Schiffrin EL. Resistance artery mechanics, structure, and extracellular components in spontaneously hypertensive rats: effects of angiotensin receptor antagonism and converting enzyme inhibition. Circulation 1999; 100:2267-2275.
2. Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ Jr, Cuddy TE, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992; 327:669-677.
3. Okunishi H, Miyazaki M, Toda N. Evidence for a putatively new angiotensin II-generating enzyme in the vascular wall. J Hypertens 1984; 2:277-284.
4. Gondo M, Maruta H, Arakawa K. Direct formation of angiotensin II without renin or converting enzyme in the ischemic dog heart. Jpn Heart J 1989; 2:219-229.
5. Ohmichi N, Iwai N, Kinoshita M. Expression of angiotensin converting enzyme and chymase in human atria. J Hypertens 1997; 15:935-943.
6. Le Trong H, Neurath H, Woodbury RG. Substrate specificity of the chymotrypsin-like protease in secretory granules isolated from rat mast cells. Proc Natl Acad Sci USA 1987; 84:364-367.
7. Caughey GH, Viro NF, Ramachandran J, Lazarus SC, Borson DB, Nadel JA. Dog mastocytoma tryptase: affinity purification, characterization, and amino-terminal sequence. Arch Biochem Biophys 1987; 258:555-563.
8. Takai S, Shiota N, Yamamoto D, Okunishi H, Miyazaki M. Purification and characterization of angiotensin II-generating chymase from hamster cheek pouch. Life Sci 1996; 58:591-597.
9. Takai S, Shiota N, Kobayashi S, Matsumura E, Miyazaki M. Induction of chymase that forms angiotensin II in the monkey atherosclerotic aorta. FEBS Lett 1997; 412:86-90.
10. Urata H, Kinoshita A, Misono KS, Bumpus FM, Husain A. Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart. J Biol Chem 1990; 265:22348-22357.
11. Wintroub BU, Schechter NB, Lazarus GS, Kaempfer CE, Schwartz LB. Angiotensin I conversion by human and rat chymotryptic proteinases. J Invest Dermatol 1984; 83:336-339.
12. Nakano A, Kishi F, Minami K, Wakabayashi H, Nakaya Y, Kido H. Selective conversion of big endothelins to tracheal smooth muscle-constricting 31-amino acid-length endothelins by chymase from human mast cells. J Immunol 1997; 159:1987-1992.
13. Takai S, Shiota N, Jin D, Miyazaki M. Chymase processes big-endothelin-2 to endothelin-2-(1-31) that induces contractile responses in the isolated monkey trachea. Eur J Pharmacol 1998; 358:229-233.
14. Azizi M, Guyene TT, Chatellier G, Wargon M, Menard J. Additive effects of losartan and enalapril on blood pressure and plasma active renin. Hypertension 1997; 29:634-640.
15. Stergiou GS, Skeva II, Baibas NM, Roussias LG, Kalkana CB, Achimastos AD, Mountokalakis TD. Additive hypotensive effect of angiotensin-converting enzyme inhibition and angiotensin-receptor antagonism in essential hypertension. J Cardiovasc Pharmacol 2000; 35:937-941.
16. Iwai N, Katsuya T, Mannami T, Higaki J, Ogihara T, Kokame K, et al. Association between SAH, an acyl-CoA synthetase gene, and hypertriglyceridemia, obesity, and hypertension. Circulation 2002; 105:41-47.
17. Okunishi H, Oka Y, Shiota N, Kawamoto T, Song K, Miyazaki M. Marked species-difference in the vascular angiotensin II-forming pathways: humans versus rodents. Jpn J Pharmacol 1993; 62:207-210.
18. Wolny A, Clozel JP, Rein J, Mory P, Vogt P, Turino M, et al. Functional and biochemical analysis of angiotensin II-forming pathways in the human heart. Circ Res 1997; 80:219-227.
19. Takai S, Sakonjo H, Fukuda K, Jin D, Sakaguchi M, Kamoshita K, et al. A novel chymase inhibitor, 2-(5-formylamino-6-oxo-2-phenyl-1,6-dihydropyrimidine- 1-yl)-N-[{3,4-dioxo-1-phenyl-7-(2-pyridyloxy)}2-heptyl]acetamide (NK3201), suppressed intimal hyperplasia after balloon injury. J Pharmacol Exp Ther 2003; 304:841-844.
20. Hara M, Ono K, Hwang MW, Iwasaki A, Okada M, Nakatani K, et al. Evidence for a role of mast cells in the evolution to congestive heart failure. J Exp Med 2002; 195:375-381.